Compare Ascendis Pharma A/S (ASND) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Invesco WilderHill Clean Energy ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Invesco WilderHill Clean Energy ETF trades at $35. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | PBW | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $46.99 |
52-Week Low | $163.32 | $22.11 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PBW trades at $35.22, down 1.29% with bearish technical signals from moving averages. The clean energy ETF shows mixed sentiment with supportive industry trends but faces volatility from interest rate sensitivity. Recent news highlights clean energy sector gains driven by energy security concerns and data center demand, though the ETF experienced significant one-day losses tied to Treasury yield movements.
Outlook remains cautious given technical weakness and rate sensitivity, though long-term clean energy tailwinds provide opportunity. Key risks include interest rate volatility and sector competition, requiring careful position sizing amid ongoing market turbulence in growth sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
